louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02418247: Minimize Radioactive Iodine Ablation Of Remnant Thyroid in Differentiated Thyroid Cancer
Official title: Phase Ⅱ Non-randomized Multicenter Controlled Trial About Effect of Remnant Ablation Therapy on the Recurrence in Low-risk Differentiated Thyroid Cancer Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
PHASE3
Conditions: Thyroid Neoplasms
Keywords: radioactive iodine therapy
ablation
thyroid cancer
Lead sponsor: National Cancer Center, Korea
Sponsor class: OTHER_GOV
First posted: 2015-04-16
Enrollment: 556
Sex: ALL
Minimum age (years): 18
Maximum age (years): 79
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The researchers investigated the rate of biochemical remission in patients without radioactive iodine therapy compared to patients with low dose radioactive iodine treatment in differentiated thyroid cancer patients who underwent total thyroidectomy.


Eligibility criteria: Inclusion Criteria:

* patients with differentiated thyroid cancer
* recently underwent total thyroidectomy (within 6 months)
* pathological criteria

  1. T1bN0 : Tumor size 1-2cm with no microscopic extension with multifocality (within three foci)
  2. T3N0 : Tumor size \<=2cm with microscopic extension (less than strap muscle)
  3. T1-3N1a : 3 or less micrometastatic lymph node

Exclusion Criteria:

* differentiated thyroid cancer with aggressive variant, poorly differentiated thyroid cancer, medullary thyroid cancer, anaplastic thyroid cancer
* gross extension (strap muscle or more)
* thyroid cancer with distant metastasis
* previous remote history of thyroid cancer surgery
* history of cervical external beam radiation therapy
* previous history of comorbid cancer within 5 years
* renal insufficiency (Ccr \<30ml/min)
* women with pregnancy or breast feeding

Primary outcomes:
measure: Biochemical Remission Rate
timeFrame: within 1 year since first thyroid hormone withdrawal regardless of radioactive iodine administration
Secondary outcomes:
Other outcomes:
Locations:
city: Daejun
country: Korea, Republic of
facility: Chungnam National University Hospital
city: Goyang
country: Korea, Republic of
facility: National Cancer Center, Korea
city: Seoul
country: Korea, Republic of
facility: Seoul National University Boramae Medical Center
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
city: Sungnam
country: Korea, Republic of
facility: Seoul National University Bundang Hospital
Study officials:
affiliation: National Cancer Center, Korea
name: Eun Kyung Lee, M.D.,Ph.D.
role: STUDY_CHAIR
References:
Clinical trial NCT05202847: Clinial Application of Park et al.(The Knee 27 (2020) 1577-1584)'s Study
Official title: Pulsed Radiofrequency Ablation to the Modified Ablation Points for Chronic Knee Pain Due to Osteoarthritis: Preliminary Prospective Randomized Controlled Study
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Knee Osteoarthritis
Lead sponsor: Gangnam Severance Hospital
Sponsor class: OTHER
First posted: 2022-01-24
Enrollment: 0
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The goal of this study was to perform pulsed radiofrequency ablation with a modified target suggested in the cadaver study by Park et al. (The Knee 27 (2020) 1577-1584) on knee osteoarthritis patients, and to evaluate the effect of reducing the frequency of intravascular injection and reducing pain.


Eligibility criteria: Inclusion Criteria:

1. chronic knee pain that does not respond to conservative treatment (physiotherapy, oral analgesic, steroid intra-articular injection, Hyruan injection) for more than 6 months
2. A score of 6 or higher (out of 10) on the target knee's numerical rating scale
3. Knee osteoarthritis 1-4 confirmed in knee X ray within 6 months of study enrollment

Exclusion Criteria:

1. Systemic inflammatory diseases such as rheumatic diseases
2. uncontrolled diabetes
3. malignant tumor
4. If the target knee has a previous surgical history (arthroscopy, arthroscopy, autologous or allograft osteochondral transplantation and autologous cartilage cell transplantation, osteotomy, arthritis surgery)
5. Patients with lidocaine and contrast agent allergy
6. history of nerve block in the target knee within 2 weeks
7. Body mass index over 40 kg/m2
8. bleeding disorder
9. Pregnant/lactating women
10. Inability to understand informed consent and respond to research questionnaires due to cognitive impairment
11. Unable to read consent form (e.g. illiterate, foreigner, etc.)

Primary outcomes:
measure: The rate at which vascular uptake is confirmed when the first contrast agent is given after the needle is positioned at the target point
timeFrame: during the ablation procedure
Secondary outcomes:
measure: numeric rating score
timeFrame: Before the pulsed radiofrequency ablation, after 4 weeks of the ablaion, after 8 weeks of the ablation, after 12 weeks of the ablation
measure: functional status
timeFrame: Before the pulsed radiofrequency ablation, after 4 weeks of the ablaion, after 8 weeks of the ablation, after 12 weeks of the ablation
measure: quality of life
timeFrame: Before the pulsed radiofrequency ablation, after 4 weeks of the ablaion, after 8 weeks of the ablation, after 12 weeks of the ablation
measure: medication
timeFrame: Before the pulsed radiofrequency ablation, after 4 weeks of the ablaion, after 8 weeks of the ablation, after 12 weeks of the ablation
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02901847: To Evaluate the Introduction of a Public Health Approach to Peripheral Arterial Disease (PAD) Using National Centre for Sport and Exercise Medicine Facilities.
Official title: To Evaluate the Introduction of a Public Health Approach to Peripheral Arterial Disease (PAD) Using National Centre for Sport and Exercise Medicine Facilities.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Peripheral Arterial Disease
Lead sponsor: Sheffield Teaching Hospitals NHS Foundation Trust
Sponsor class: OTHER
First posted: 2016-09-15
Enrollment: 21
Sex: ALL
Minimum age (years): 50
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: The aim of the project is to investigate the clinical and patient centred outcomes of people with Peripheral Arterial Disease (PAD) attending a podiatry led integrated care pathway, utilising advice on diet, activity and smoking cessation. The podiatry clinic will be delivered from the Move More centre (NCSEM) and participants will be encouraged to access these facilities as part of their activity programme which will be agreed with the physical activity team. Primary and secondary outcomes will be clinical - claudication pain, distance walked at 3 and 6 months, blood pressure and lipid monitoring, weight management, reduced BMI, and the success of any smoking cessation. Quality of life and patient satisfaction with the programme will also be assessed.


Eligibility criteria: Inclusion Criteria:

1. adult patient between the ages of 50-90 years,
2. Patient attending for podiatry treatment
3. diagnosis of PAD or is showing signs of symptoms of PAD
4. wishes to take part in the study.

Exclusion Criteria:

1. Anyone unable to give informed consent due to lack of mental capacity.
2. Anyone who would be unable to participate in increased activity due to other co-morbidities

Primary outcomes:
measure: Distance walked before onset of intermittent claudication
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Sheffield
country: United Kingdom
facility: Sheffield Teaching Hospitals NHS Foundation Trust
Study officials:
References:
Clinical trial NCT06951347: Prophylactic Sodium Supplementation for Children Hospitalized With Pneumonia
Official title: Impact of Prophylactic Sodium Supplementation on Hospital Outcomes in Infants and Children With Pneumonia. A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Childhood Pneumonia
Lead sponsor: General Organization for Teaching Hospitals and Institutes
Sponsor class: OTHER
First posted: 2025-04-30
Enrollment: 140
Sex: ALL
Minimum age (years): 1
Maximum age (years): 5
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The goal of this clinical trial is to study the impact of sodium supplementation on hospital outcomes of children with pneumonia.

It aims to answer:

* Does sodium supplementation lower the length of hospital stay in children with pneumonia?
* Does potassium supplementation lower the length of hospital stay in children with pneumonia?

Researchers will compare the intervention arm to a placebo arm to see if the intervention lowers the length of hospital stay.

Participants will:

• Take one sachet of oral rehydration solution (ORS) every day for 3 days.

Detailed description: The study is a randomized clinical trial that will be conducted on hospitalized children with pneumonia after considering exclusion criteria.

The enrolled children will be randomly divided into two groups. The intervention group will receive oral rehydration solution (ORS), and the placebo group will receive a placebo. Children will receive either the ORS or the placebo daily for 3 days.

All children will be followed until discharge from the hospital, and their clinical outcomes will be assessed.

Eligibility criteria: Inclusion Criteria:

* Infants and children aged between 1 month and 5 years.
* Patients diagnosed with pneumonia according to World Health Organization (WHO) criteria.

Exclusion Criteria:

* Children with other comorbidities.
* Those whose parents will show disapproval for the participation of the study.
* Children on medications that affect sodium and potassium levels.

Primary outcomes:
measure: The difference in hospital length of stay between hospitalized children with pneumonia who received oral rehydration solution and those who did not receive it
timeFrame: Children will be followed until discharge from the hospital, an average of one week.
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Mataria Teaching Hospital
Study officials:
affiliation: Mataria Teaching Hospital, General Organization for Teaching Hospitals and Institutes, Cairo, Egypt
name: Marwa Taha, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Faculty of Medicine, Cairo University, Cairo, Egypt
name: Hoda Atef Abdelsattar Ibrahim, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00905047: Xeloda or UFT (Tegafur-uracil) With Folinic Acid in Advanced or Metastatic Colorectal Cancer
Official title: Open Comparative Study With a Cross-over According to Patients'Preference Receiving Xeloda or UFT With Folinic Acid in Advanced or Metastatic Colo-rectal Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Colorectal Cancer
Keywords: colo-rectal cancer
advanced
metastatic
locally advanced or metastatic colo-rectal cancer
Lead sponsor: Centre Oscar Lambret
Sponsor class: OTHER
First posted: 2009-05-20
Enrollment: 89
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The scope of the trial is to determine the preference of patients, after randomization and cross-over, for one of the two treatments.

Another objective of the trial is to assess and compare the safety of each treatment.

Detailed description: Further study details as provided by Centre Oscar Lambret.

Eligibility criteria: Inclusion Criteria:

* Locally advanced or metastatic colo-rectal cancer
* Age \> or = 18 years old
* PS-WHO \< or = 2
* Polynuclear neutrophil leukocytes \> or = 1500/mm3, platelets \> or = 100000/mm3
* Total bilirubin \< or = 3 ULN, ASAT-ALAT \< or = 2.5 ULN
* Effective contraception
* Written informed consent signed

Exclusion Criteria:

* Concomitant radiotherapy
* Contraindication to fluoropyrimidines
* Treatment with sorivudine and its chemical analogs such as brivudine
* Severe hepatic insufficiency
* Severe renal insufficiency
* Pregnant or lactating woman
* Hypersensitivity to capecitabine, 5FU, tegafur or one of its excipients

Primary outcomes:
measure: patients preference after randomization and cross-over
timeFrame: after 2 cycles of treatment
Secondary outcomes:
measure: safety of each treatment
timeFrame: at day 56 (after two cycles of treatment)
Other outcomes:
Locations:
city: Angers
country: France
facility: Centre Paul Papin
city: Armentieres
country: France
facility: Centre Hospitalier
city: Beuvry
country: France
facility: Centre Hospitalier de Béthune
city: Cholet
country: France
facility: Centre Hospitalier de CHOLET
city: Dechy
country: France
facility: Centre Leonard de Vinci
city: Lille
country: France
facility: Polyclinique du Bois
city: Lille
country: France
facility: Centre Oscar Lambret
city: Lille
country: France
facility: Hopital Saint Vincent de Paul
city: Lille
country: France
facility: Centre Hospitalier Regional
city: Roubaix
country: France
facility: Centre Hospitalier
city: Saint Martin les Boulogne
country: France
facility: Centre Joliot-Curie
city: Valenciennes
country: France
facility: Centre Hospitalier
city: Valenciennes
country: France
facility: Clinique des Dentellieres
Study officials:
affiliation: Centre Oscar Lambret
name: ADENIS Antoine, MD,PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04828447: Recipe for Heart Health
Official title: Recipe for Heart Health: A Plant-Based Culinary Diet Intervention to Test Independent Benefits of Olive Oil
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Atherosclerotic Cardiovascular Disease
Lead sponsor: University of Florida
Sponsor class: OTHER
First posted: 2021-04-02
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: Pilot prospective randomized crossover clinical trial
Primary purpose: OTHER

Brief summary: The overall objectives of this project are to compare clinical parameters in moderate risk Atherosclerotic Cardiovascular Disease (ASCVD) patients following a Whole Food Plant Based (WFPB) diet containing a high (4 TB) compared to a low (\<1 tsp) amount of raw extra virgin olive oil.

Detailed description: Up to sixty-eight primary prevention outpatient adults with intermediate to high ASCVD risk factors will be randomized in a crossover fashion to follow a WFPB diet without animal products that is either high (4 tablespoons) or low (\< \~1 teaspoon) in raw extra virgin olive oil. After confirming eligibility and patients provide consent, the research team will randomize the participant at the baseline visit. The baseline visit and run-in visit 1 will follow as described below. With the intent of recruiting cohorts of ten, a group of participants will subsequently begin the first Whole Food Plant Based culinary diet intervention for four weeks, followed by a one-week (+ 3 days) washout period before switching to the opposite oil diet for an additional four weeks. During each of the 4-week interventions, participants will attend weekly cooking sessions that align with the dietary intervention with a registered dietitian. Patients will be asked to maintain levels of physical activity through the duration of the study. Data will be collected at the patient's cardiology visits before and after each diet intervention for a total of four in-person visits excluding the screening visit.

Eligibility criteria: Inclusion Criteria:

-Adult patients with borderline to high risk for ASCVD

Exclusion Criteria:

-Adult patients with known cardiovascular disease

Primary outcomes:
measure: Low Density Lipoprotein-Cholesterol
timeFrame: 4 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Gainesville
country: United States
facility: University of Florida
state: Florida
Study officials:
affiliation: University of Florida
name: Monica Aggarwal, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00838747: Measurement of the Folate Receptor in Blood
Official title: Measurement of the Folate Receptor in Blood
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Healthy
Keywords: folate receptor
blood samples
ovarian cancer
development of measure of folate receptor in blood samples
possible selection of patients for treatment with FR targeted agents
Lead sponsor: Royal Marsden NHS Foundation Trust
Sponsor class: OTHER
First posted: 2009-02-06
Enrollment: 7
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with ovarian cancer and healthy volunteers

Brief summary: The folate receptor (FR) is a cell marker that is over expressed on the cell surface of certain cancers, this occurs most frequently in ovarian cancers. Some normal tissues also express the FR, however in these normal tissues the FR is usually located on the tissue surface that is inaccessible to circulating drugs. As such, drugs which target the FR may potentially be used to achieve anti-tumour efficacy whilst reducing toxicity to normal tissues. Therefore the ability to measure FR levels from different cancer types may help to select patients who are most likely to benefit from treatment with FR targeted therapies. One such drug BGC 945 is currently being tested in preclinical study at The Institute of Cancer Research

Detailed description: A method has been developed in the laboratory which has been able to measure FR obtained from cancer cells in culture that has been added into blood. We would like to study if this method can measure FR in plasma and serum obtained from patients with ovarian cancer. We would also like to analyse plasma and serum samples obtained from healthy volunteers to determine if they have any appreciable levels of FR, which can then be compared to the measurements obtained from cancer patients.

Eligibility criteria: Inclusion Criteria:

* Patients with stage III/IV ovarian cancer
* healthy volunteers who are staff at the ICR and RMH

Exclusion Criteria:

* patients or healthy volunteers who are unable to give informed consent
* pregnancy

Primary outcomes:
measure: To measure the levels of folate receptor in blood samples obtained from patients with ovarian cancer and from healthy volunteers
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: London
country: United Kingdom
facility: Royal Marsden NHS Foundation Trust
state: Sutton
Study officials:
affiliation: Royal Marsden NHS Foundation Trust
name: Stan Kaye, Professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00932347: Effect of Mouthwash Containing Camellia Sinensis Extracts on Oral Malodor
Official title: Effect of Mouthwash Containing Camellia Sinensis Extracts on Oral Malodor, Plaque and Papillary Bleeding Indices in Gingivitis Patients.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Gingivitis
Halitosis
Keywords: Camellia sinensis
volatile sulfur compounds
Lead sponsor: Mahidol University
Sponsor class: OTHER
First posted: 2009-07-03
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine effect of Mouthwash containing Camellia sinensis extracts on oral malodor and gingival inflammation in gingivitis subjects.

Detailed description: At baseline, level of volatile sulfur compounds (VSC) in mouth air, Plaque Index and Papillary Bleeding Index will be recorded. Gingivitis subjects will be asked to rinse with Camellia sinensis mouthwash or placebo mouthwash. VSC level will be measured at 30 minutes and 3 hours post-rinsing. For the following 4 weeks, subjects will be rinsed with the assigned mouthwash twice daily after toothbrushing. All parameter will be recorded again at Day 28.

Eligibility criteria: Inclusion Criteria:

* at least 20 teeth
* clinical diagnosis as plaque induced gingivitis
* having over 80 ppb of volatile sulfur compounds in mouth air

Exclusion Criteria:

* smoker
* denture wearer
* having systemic diseases or oral pathology
* taking antibiotics 1 month prior to study

Primary outcomes:
measure: level of volatile sulfur compounds in mouth air (part per billion)
timeFrame: baseline, 30 minutes, 3 hours, 28 days
Secondary outcomes:
measure: Papillary bleeding index
timeFrame: baseline, 28 days
Other outcomes:
Locations:
city: Bangkok
country: Thailand
facility: Post Graduate Clinic 2, Faculty of Dentistry, Mahidol University
Study officials:
affiliation: Department of Oral Medicine, Faculty of Dentistry, Mahidol University
name: Supanee Rassameemasmaung, Ph.D
role: PRINCIPAL_INVESTIGATOR
References: